NCT03718091
|
Phase II |
VX-970
|
M6620 (VX-970) in Selected Solid Tumors |
Recruiting |
NCT03297606
|
Phase II |
Bosutinib
Palbociclib
Vismodegib
Nivolumab + Ipilimumab
Vemurafenib + Cobimetinib
Temsirolimus
Olaparib
Erlotinib
Crizotinib
Sunitinib
Afatinib
Dasatinib
Pertuzumab + Trastuzumab
Axitinib
|
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) |
Recruiting |
NCT02873975
|
Phase II |
Prexasertib
|
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency |
Recruiting |